# Malin Corporation

> Malin Corporation is a VC fund backing Biotechnology and Health Care. See 16 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Dublin, Ireland
- Total investments: 16
- Last investment: Aug 2023
- Lead investor: 50%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/malin-plc/
- X (Twitter): https://twitter.com/Malin_plc
- Website: http://www.malinplc.com

Malin Corporation is a VC fund in Dublin focused on Biotechnology and Health Care. Malin Corporation plc (“Malin”) is an Irish incorporated public limited company whose head office is in Dublin, Ireland with subsidiary offices in New Haven, Connecticut and Research Triangle, North Carolina, USA.Malin’s purpose is to create shareholder value through the selective long-term application of capital and operational expertise toprivate, pre-IPO, pre-trade sale operating businesses in dynamic and fast growing segments of the life sciences industry. Through its operational involvement, Malin works with its investee companies to enable them to reach the full potential of their value proposition and to achieve commercial success.

## Contacts

5 contacts available for Malin Corporation. Shizune tracks 4 team members at Malin Corporation. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/malin-corporation-plc?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Series B | $31M–$50M |
| Series C | $100M–$142M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 8 | 50% |
| Health Care | 7 | 44% |
| Biopharma | 3 | 19% |
| Medical | 2 | 13% |
| Therapeutics | 2 | 13% |

16 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Funding Round | 6 | 38% |
| Series B | 2 | 13% |
| Series C | 2 | 13% |
| Series A | 1 | 6% |
| Series E | 1 | 6% |

8 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 7 | 44% |
| United Kingdom | 2 | 13% |
| Ireland | 1 | 6% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Adrian Howd | CEO | 2 | https://shizune.co/investors/profile/adrian-howd |
| John Given | Chairman | 1 | https://shizune.co/investors/profile/john-given |
| Rudy Mareel | Non Executive Director | 0 | https://shizune.co/investors/profile/rudy-mareel |
| Sean Murphy | Co-Founder | 0 | https://shizune.co/investors/profile/sean-murphy-c74a |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| CG Oncology | CG Oncology formerly known as Cold Genesys is a privately-held, clinical-stage biopharmaceutical company focused on the research, acquisition, and development of novel immunotherapies. It specializes in the development of oncolytic immunotherapies to combat cancer, providing patients with new and impactful therapies.CG Oncology acquired therights to develop CG0070 from BioSante Pharmaceuticals (Nasdaq: BPAX). A phase I/IIa dose-escalating clinical trial has already completed in 35 patients with NMIBC. Cold Genesys is hopeful to get this therapy back into the clinical setting with the initiation of the proposed phase II/III trial. | $105M | Series F | Aug 02, 2023 | https://www.cgoncology.com |
| CG Oncology | CG Oncology formerly known as Cold Genesys is a privately-held, clinical-stage biopharmaceutical company focused on the research, acquisition, and development of novel immunotherapies. It specializes in the development of oncolytic immunotherapies to combat cancer, providing patients with new and impactful therapies.CG Oncology acquired therights to develop CG0070 from BioSante Pharmaceuticals (Nasdaq: BPAX). A phase I/IIa dose-escalating clinical trial has already completed in 35 patients with NMIBC. Cold Genesys is hopeful to get this therapy back into the clinical setting with the initiation of the proposed phase II/III trial. | $120M | Series E | Nov 15, 2022 | https://www.cgoncology.com |
| Poseida Therapeutics | Poseida Therapeutics is a clinical-stage biopharmaceutical company dedicated to utilizing our proprietary gene engineering platform technologies to create next generation cell and gene therapeutics with the capacity to cure.We have discovered and are developing a broad portfolio of product candidates in a variety of indications based on our coreproprietary platforms, including our non-viral piggyBac DNA Modification System, Cas-CLOVER site-specific gene editing system and nanoparticle- and AAV-based gene delivery technologies. Our core platform technologies have utility, either alone or in combination, across many cell and gene therapeutic modalities and enable us to engineer our wholly-owned portfolio of product candidates that are designed to overcome the primary limitations of current generation cell and gene therapeutics. | $142M | Series C | Apr 22, 2019 | http://poseida.com/ |
| Poseida Therapeutics | Poseida Therapeutics is a clinical-stage biopharmaceutical company dedicated to utilizing our proprietary gene engineering platform technologies to create next generation cell and gene therapeutics with the capacity to cure.We have discovered and are developing a broad portfolio of product candidates in a variety of indications based on our coreproprietary platforms, including our non-viral piggyBac DNA Modification System, Cas-CLOVER site-specific gene editing system and nanoparticle- and AAV-based gene delivery technologies. Our core platform technologies have utility, either alone or in combination, across many cell and gene therapeutic modalities and enable us to engineer our wholly-owned portfolio of product candidates that are designed to overcome the primary limitations of current generation cell and gene therapeutics. | $30.5M | Series B | Apr 03, 2018 | http://poseida.com/ |
| Poseida Therapeutics | Poseida Therapeutics is a clinical-stage biopharmaceutical company dedicated to utilizing our proprietary gene engineering platform technologies to create next generation cell and gene therapeutics with the capacity to cure.We have discovered and are developing a broad portfolio of product candidates in a variety of indications based on our coreproprietary platforms, including our non-viral piggyBac DNA Modification System, Cas-CLOVER site-specific gene editing system and nanoparticle- and AAV-based gene delivery technologies. Our core platform technologies have utility, either alone or in combination, across many cell and gene therapeutic modalities and enable us to engineer our wholly-owned portfolio of product candidates that are designed to overcome the primary limitations of current generation cell and gene therapeutics. | $11.2M | Series A | Aug 02, 2017 | http://poseida.com/ |
| Xenex | Xenex is offering an effective approach to reducing the incidence of healthcare-associated infections.The Xenex mission is to save lives and reduce suffering by destroying deadly microorganisms that can cause hospital-acquired infections (HAIs). Xenex’s Pulsed Xenon Full Spectrum™ UV Disinfection Solution reduces the bacterial load oftenassociated with an increased risk for HAIs. Since its commercial launch in June 2010, Xenex devices are now included in infection control protocols in almost three hundred hospitals throughout the U.S.Xenex was founded in 2009 and headquartered in San Antonio, Texas. | $38M |  | Feb 24, 2017 | http://xenex.com |
| Artizan Biosciences | Artizan Biosciences provides pharmaceutical drug development services, namely, the development of small molecule drugs for use in humans. The Durham-based biotech company declined to disclose its intended use of the proceeds from this offering, as well as its current revenue range. |  |  | Feb 06, 2017 | http://artizanbiosciences.com/ |
| Wren Therapeutics | Wren Therapeutics is a biopharmaceutical company based in Cambridge UK, focused on drug discovery and development for protein misfolding diseases, which include Alzheimer’s and Parkinson’s diseases, type-2 diabetes, and many rare forms of amyloidosis. Wren’s proprietary technology platform is built on new and fundamental understanding of theorigins of these diseases and is based on decades of scientific research at the University of Cambridge and Lund University. Wren is using this platform to develop small molecule therapeutics for multiple protein misfolding diseases, including major neurological and rare disorders. |  |  | Jan 16, 2017 | http://www.wrentherapeutics.com/ |
| Kymab | Kymab is a clinical-stage biopharmaceutical company developing fully human monoclonal antibody therapeutics with a focus on immune-mediated diseases and immuno-oncology using its proprietary, integrated platforms collectively called IntelliSelect®. Kymab’s IntelliSelect Transgenic platforms contain a full diversity of human antibodies, making themthe most comprehensive antibody platforms available. The company was founded in 2010 and is based in Cambridge, the United Kingdom. | $100M | Series C | Nov 24, 2016 | http://www.kymab.com |
| Poseida Therapeutics | Poseida Therapeutics is a clinical-stage biopharmaceutical company dedicated to utilizing our proprietary gene engineering platform technologies to create next generation cell and gene therapeutics with the capacity to cure.We have discovered and are developing a broad portfolio of product candidates in a variety of indications based on our coreproprietary platforms, including our non-viral piggyBac DNA Modification System, Cas-CLOVER site-specific gene editing system and nanoparticle- and AAV-based gene delivery technologies. Our core platform technologies have utility, either alone or in combination, across many cell and gene therapeutic modalities and enable us to engineer our wholly-owned portfolio of product candidates that are designed to overcome the primary limitations of current generation cell and gene therapeutics. | $23M | Series A | Dec 23, 2015 | http://poseida.com/ |

10 of 16 investments shown.

## Co-investors
- [Longitude Capital](https://shizune.co/investors/profile/longitude-capital) — VC Fund, 5 deals together
- [Acorn Bioventures](https://shizune.co/investors/profile/acorn-bioventures) — VC Fund, 2 deals together
- [Ally Bridge Group](https://shizune.co/investors/profile/ally-bridge-group) — VC Fund, 2 deals together
- [Decheng Capital](https://shizune.co/investors/profile/decheng-capital) — VC Fund, 2 deals together
- [ORI Capital](https://shizune.co/investors/profile/ori-capital) — VC Fund, 2 deals together
- [RA Capital Management](https://shizune.co/investors/profile/ra-capital-management) — VC Fund, 2 deals together

## Similar investors

### Similar industry
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund

### Similar stage
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund
- [SFC Capital](https://shizune.co/investors/profile/startup-funding-club) — VC Fund
- [HTGF (High-Tech Gruenderfonds)](https://shizune.co/investors/profile/high-tech-gr%C3%BCnderfonds) — VC Fund

### Similar country
- [Enterprise Ireland](https://shizune.co/investors/profile/enterprise-ireland) — VC Fund
- [NDRC](https://shizune.co/investors/profile/ndrc) — VC Fund
- [Act Venture Capital](https://shizune.co/investors/profile/act-venture-capital) — VC Fund

## Featured in investor lists
- [Fitness VC Funds in Ireland](https://shizune.co/investors/fitness-vc-funds-ireland)
- [Medical VC Funds in Ireland](https://shizune.co/investors/medical-vc-funds-ireland)
- [Hardware VC Funds in Ireland](https://shizune.co/investors/hardware-vc-funds-ireland)
- [Sports Investors in Ireland](https://shizune.co/investors/sports-investors-ireland)
- [Fitness Investors in Ireland](https://shizune.co/investors/fitness-investors-ireland)
- [Health Care VC Funds in Ireland](https://shizune.co/investors/health-care-vc-funds-ireland)

## FAQ

### What does Malin Corporation invest in?

Malin Corporation invests primarily in Biotechnology, Health Care and Biopharma startups, most often at Funding Round and Series B stage. Most of the 16 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Malin Corporation's check size?

Malin Corporation typically joins rounds of $31M–$50M at Series B and $100M–$142M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Malin Corporation participates in.

### How do I contact Malin Corporation?

Public channels for Malin Corporation include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Malin Corporation?

The team at Malin Corporation includes Adrian Howd (CEO), John Given (Chairman) and Rudy Mareel (Non Executive Director). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co